JILIN AODONG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.89 CNY | -2.30% |
|
+1.36% | -1.65% |
| Apr. 17 | Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20% | MT |
| Apr. 16 | Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 17,020 | 17,098 | 17,807 | - |
| Enterprise Value (EV) 1 | 17,020 | 17,098 | 17,807 | 17,807 |
| P/E ratio | 10.2 x | 12.3 x | 7.68 x | 6.63 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 4.96 x | 4.4 x | 3.8 x |
| EV / Revenue | - | 4.96 x | 4.4 x | 3.8 x |
| EV / EBITDA | - | 10.7 x | 7.05 x | 6.13 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 0.66 x | 0.58 x | 0.55 x |
| Nbr of stocks (in thousands) | 1,135,395 | 1,129,349 | 1,195,895 | - |
| Reference price 2 | 14.99 | 15.14 | 14.89 | 14.89 |
| Announcement Date | 4/18/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 3,449 | 4,046 | 4,690 |
| EBITDA 1 | - | 1,593 | 2,528 | 2,903 |
| EBIT 1 | - | 1,382 | 2,253 | 2,658 |
| Operating Margin | - | 40.08% | 55.69% | 56.66% |
| Earnings before Tax (EBT) 1 | - | 1,500 | 2,254 | 2,659 |
| Net income 1 | 1,781 | 1,460 | 2,329 | 2,692 |
| Net margin | - | 42.33% | 57.55% | 57.4% |
| EPS 2 | 1.467 | 1.227 | 1.940 | 2.245 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/18/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 5.48% | 7.6% | 8.37% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | 22.80 | 25.50 | 27.30 |
| Cash Flow per Share 2 | - | 0.0600 | 0.7300 | - |
| Capex 1 | - | 385 | 33.7 | 33.2 |
| Capex / Sales | - | 11.16% | 0.83% | 0.71% |
| Announcement Date | 4/18/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.89
CNY
Average target price
22.67
CNY
Spread / Average Target
+52.25%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.65% | 2.52B | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B |
- Stock Market
- Equities
- 000623 Stock
- Financials Jilin Aodong Pharmaceutical Group Co., Ltd.
